Tevogen Bio's International Patent Application Published By WIPO For AI-Based Peptide Prediction System

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (NASDAQ:MSFT) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases.

Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. Tevogen.AI's proprietary approach may overcome these challenges by:

• Efficiently screening and ranking potential peptides based on their immunological activity.
• Eliminating peptides likely to be ineffective due to self-tolerance or human genome overlap.
• Continuously refining predictions using real-world data to train and enhance machine learning models.